Meeting
2018 Gastrointestinal Cancers Symposium
Points to keep in mind when carrying out clinical trials in Japan on advanced pancreatic cancer cases without alternative treatments: Analysis of 367 cases.
Authors
Giichiro Tsurita
University of Tokyo Institute of Medical Science, Tokyo, Japan
Giichiro Tsurita , Hiroshi Yasui , Tomohiro Kurokawa , Yuichiro Yoshioka , Kentaro Yazawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 243)
DOI
10.1200/JCO.2018.36.4_suppl.243
Abstract #
243
Poster Bd #
B18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO).
First Author: Inna Markovna Chen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
First Author: Bomi Kim
Poster
2022 ASCO Quality Care Symposium
Reducing preventable ED visits in patients with advanced NSCLC: Collective insights from three cancer centers.
First Author: Wendi Waugh
Poster
2022 ASCO Annual Meeting
A multicenter, randomized, double-blind phase III clinical study to evaluate the efficacy and safety of KN046 combined with nab-paclitaxel and gemcitabine versus placebo combined with nab-paclitaxel and gemcitabine in patients with advanced pancreatic cancer (ENREACH-PDAC-01).
First Author: Gang Jin